Volgen
Margaretha GM Roemer
Margaretha GM Roemer
Post-doc, Amsterdam UMC, location VUmc
Geverifieerd e-mailadres voor vumc.nl
Titel
Geciteerd door
Geciteerd door
Jaar
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
B Chapuy, C Stewart, AJ Dunford, J Kim, A Kamburov, RA Redd, ...
Nature medicine 24 (5), 679-690, 2018
14932018
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, ...
The Lancet Oncology 17 (9), 1283-1294, 2016
9872016
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies
BJ Chen, B Chapuy, J Ouyang, HH Sun, MGM Roemer, ML Xu, H Yu, ...
Clinical Cancer Research 19 (13), 3462-3473, 2013
9362013
Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
B Chapuy, MR McKeown, CY Lin, S Monti, MGM Roemer, J Qi, PB Rahl, ...
Cancer cell 24 (6), 777-790, 2013
8092013
PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome
MGM Roemer, RH Advani, AH Ligon, Y Natkunam, RA Redd, H Homer, ...
Journal of Clinical Oncology 34 (23), 2690, 2016
7762016
Targetable genetic features of primary testicular and primary central nervous system lymphomas
B Chapuy, MGM Roemer, C Stewart, Y Tan, RP Abo, L Zhang, AJ Dunford, ...
Blood, The Journal of the American Society of Hematology 127 (7), 869-881, 2016
5112016
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma
L Nayak, FM Iwamoto, A LaCasce, S Mukundan, MGM Roemer, B Chapuy, ...
Blood 129 (23), 3071-3073, 2017
3982017
Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study
SM Ansell, MC Minnema, P Johnson, JM Timmerman, P Armand, ...
Journal of Clinical Oncology 37 (6), 481, 2019
3222019
Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma
MGM Roemer, RA Redd, FZ Cader, CJ Pak, S Abdelrahman, J Ouyang, ...
Journal of Clinical Oncology 36 (10), 942, 2018
3072018
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma
CD Carey, D Gusenleitner, M Lipschitz, MGM Roemer, EC Stack, E Gjini, ...
Blood 130 (22), 2420-2430, 2017
3032017
Classical Hodgkin lymphoma with reduced β2M/MHC class I expression is associated with inferior outcome independent of 9p24. 1 status
MGM Roemer, RH Advani, RA Redd, GS Pinkus, Y Natkunam, AH Ligon, ...
Cancer immunology research 4 (11), 910-916, 2016
1802016
Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain
M Shi, MGM Roemer, B Chapuy, X Liao, H Sun, GS Pinkus, MA Shipp, ...
The American journal of surgical pathology 38 (12), 1715, 2014
1772014
Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva
BE Howitt, HH Sun, MGM Roemer, A Kelley, B Chapuy, E Aviki, C Pak, ...
JAMA oncology 2 (4), 518-522, 2016
1262016
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva
BE Howitt, HH Sun, MGM Roemer, A Kelley, B Chapuy, E Aviki, C Pak, ...
JAMA oncology 2 (4), 518-522, 2016
1262016
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease
B Chapuy, H Cheng, A Watahiki, MD Ducar, Y Tan, L Chen, MGM Roemer, ...
Blood, The Journal of the American Society of Hematology 127 (18), 2203-2213, 2016
922016
PD-L1 and PD-L2 expression in cervical cancer: regulation and biomarker potential
J Rotman, LAS Den Otter, MCG Bleeker, SS Samuels, AM Heeren, ...
Frontiers in immunology 11, 2020
652020
Clinical validation of Whole Genome Sequencing for cancer diagnostics
P Roepman, E de Bruijn, S van Lieshout, L Schoenmaker, MC Boelens, ...
The Journal of Molecular Diagnostics, 2021
512021
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
HJ van der Horst, AV de Jonge, IH Hiemstra, AT Gelderloos, DRAI Berry, ...
Blood cancer journal 11 (2), 1-8, 2021
472021
B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency2015 SH/EAHP Workshop Report—Part 2
D De Jong, MGM Roemer, JKC Chan, J Goodlad, D Gratzinger, ...
American journal of clinical pathology 147 (2), 153-170, 2017
412017
B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency2015 SH/EAHP Workshop Report—Part 2
D de Jong, MGM Roemer, JKC Chan, J Goodlad, D Gratzinger, ...
American Journal of Clinical Pathology 147 (2), 153-170, 2017
412017
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20